Tirzepatide for weight loss in kidney transplant patients
Treatments studied
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests if tirzepatide can help people who have had a kidney transplant and are still overweight lose weight. It may be an option if you have had your transplant at least a year ago, your kidney function is stable, and your body mass index is 27 or higher.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You received a kidney transplant at least 12 months ago.
- Your body mass index (BMI) is 27 or higher, which is considered overweight or obese.
- Your kidney function has been stable over the past 3 months (a simple blood test checks this).
- Your anti-rejection medicines have not been changed recently.
- You are able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the ability to exercise and daily function in people who have heart failure with reduced pumping strength and are overweight or obese.
This study tests a medicine called tirzepatide (brand name Spartina) to see if it is safe and works well for people with chronic kidney failure. If you have diabetes or a high BMI, this trial might help improve your kidney health.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This trial looks at whether a medicine called tirzepatide (given as an injection) helps people with obesity lose weight in real life. Researchers will also see how people use the medicine, which may help doctors find better ways to treat obesity.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
Hear when a new Tirzepatide trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.